MORRISVILLE, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 2023 Health Trends ...

Syneos Health Inc. SYNH recently extended its strategic partnership with Medable — the technology platform provider for patient-centered clinical trials. The extended partnership is a part of ...

May 10 (Reuters) - An investment consortium, comprising of Elliott Investment Management, Patient Square Capital and Veritas Capital, has agreed to take Syneos Health Inc (SYNH.O), opens new tab ...

Feb 27 (Reuters) - Syneos Health Inc (SYNH.O), opens new tab is making a new effort to sell itself after a reduced backlog of contracts for providing clinical research to drug developers led to a ...

MORRISVILLE – Syneos Health is now a private company, having wrapped up its deal valued at some $7 billion with private equity partners Elliott Investment Management L.P., Patient Square ...

To this end, Syneos Health helps support pharma organisations to “join the dots” by offering end-to-end clinical and commercial services through its Biopharmaceutical Acceleration Model.

Syneos Health, a leading biopharmaceutical contract research organization, agreed to be acquired for $7.1 billion by a group of private equity firms. Elliott Investment Management, Patient Square ...

The multi-billion dollar deal to acquire Syneos Health comes amid an earnings slump for the company as the life sciences industry faces mounting headwinds. Report: $5B Triangle firm eyes sale amid ...

An awful day for the stock market turned into a terrible one for shares of Syneos Health (SYNH), which fell 13.7%. This slide was driven by an operational update provided during an investor ...

Syneos Health is a global provider of end-to-end biopharmaceutical outsourcing solutions. The Company operates through two segments, Clinical Solutions and Commercial Solutions, and provides a ...

Syneos Health merits a narrow moat in the industry. Not all of the Q3 results look bad - key figures were improved, commercial solutions business revenue growth was strong, and there's still $350 ...